Latest News-CliniExpert

Lilly and Banner Alzheimer's Institute Collaborate on Planned Phase 3 Prevention Trial of Donanemab

INDIANAPOLIS and PHOENIX, July 15, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Banner Alzheimer's Institute today announced a strategic research collaboration as part of the planned

Johnson & Johnson Single-Shot COVID-19 Vaccine Demonstrated a Durable Immune Response and Elicited Dual Mechanisms of Protection Against Delta and Other SARS-CoV-2 Variants of Concern in Data Published in New England Journal of Medicine

Antibody and T-cell immune responses strong and stable at eight months after immunization Demonstrated neutralizing antibody activity against the Delta variant (B.1.617.2) over time NEW BRUNSWICK, N.J

Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE) July 12, 2021 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced today the presentation of p

Johnson & Johnson Statement on COVID-19 Vaccine Following Reports of Guillain-Barré Syndrome

NEW BRUNSWICK, N.J., July 12, 2021 -- The safety and well-being of the people who use our products is our number one priority. Rare cases of the neurological disorder, Guillain-Barré syndrome have be

Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis

Orelabrutinib is a Phase 2 oral small molecule Bruton’s tyrosine kinase inhibitor with high selectivity and the ability to cross the blood-brain barrier InnoCare to receive a $125 million upfront paym

FDA Approves Updated Aduhelm Prescribing Information to Emphasize Population Studied in Clinical Trials

Aduhelm should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia CAMBRIDGE, Mass. and TOKYO, July 08, 2021 (GLOBE NEWSWIRE) -- Biogen (Nas

Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 7, 2021 -- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first participan

FDA Approves Bylvay (odevixibat) for the Treatment of Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)

BOSTON, July 20, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced U.S. Food & Drug Administration (

Mr. James Ho, the founder of CliniExpert, was invited to attend the 71st Indian Pharmaceutical Congress and was awarded the International Contribution Award

On December 20-22, 2019, at the invitation of the Committee of Indian Drug Control Officials, Mr. James Ho, CEO of Beijing Memorial Pharmaceutical Research Co., Ltd. went to Chennai, the fourth larges

Organized by Cliniexpert, China Pharma Summit 2021 in Beijing & First China International Generic Drug Development Forum was Successfully Held

From June 3 to 4, 2021, the "China Pharma Summit 2021 in Beijing & First China International Generic Drug Development Forum" hosted by Beijing Memorial Pharmaceutical Research Co., Ltd.

FDA Approves Fexinidazole as the First All-Oral Treatment for Sleeping Sickness

July 19, 2021 -- The US Food and Drug Administration (FDA) has approved fexinidazole as the first all-oral treatment for both stages of the Trypanosoma brucei gambiense form of sleeping sickness (Huma

FDA Approves Rezurock (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)

NEW YORK, NY / ACCESSWIRE / July 16, 2021 / -- Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has approved Rezurock™ (belumosudil) 200 mg once dai